HOME >> MEDICINE >> NEWS
Primary biliary cirrhosis more prevalent around toxic waste sites in NYC

According to a new study, exposure to toxins from hazardous waste sites may be a significant risk factor for developing primary biliary cirrhosis (PBC). Published in the March 2006 issue of Hepatology, researchers found significant clusters of the disease near Superfund toxic waste sites (SFS) and that the majority of patients in New York City who need liver transplants because of PBC, reside near SFS. Hepatology is published on behalf of the society by John Wiley & Sons, Inc., and is available online via Wiley InterScience at http://www.interscience.wiley.com/journal/hepatology.

PBC is an uncommon liver disease of unknown cause, though it reportedly appears in geographic clusters. Researchers, led by Aftab Ala, M.D. of Mount Sinai School of Medicine in New York City, examined the prevalence and potential clustering of PBC near New York City's most toxic waste sites, which are state-designated SFS.

The researchers collected zip code data on 172 patients in New York City in need of orthotopic liver transplant (OLT) between 1995 and 2003 due to either PBC or primary sclerosing cholangitis (PSC). They compared the patients' zip codes to zip codes of known SFS in the city. Of the city's 174 zip codes, 89 included or bordered SFS and 85 did not.

The researchers then calculated the expected prevalence of PBC-OLT and PSC-OLT, adjusting for demographic characteristics. They compared the mean standardized prevalence ratios in zip codes containing or adjacent to a SFS to the remaining zip codes. Lastly, they utilized SaTScan, a statistical software package, to detect specific clusters.

"The prevalence ratio of PBC-OLT, not PSC-OLT, was significantly higher in zip codes containing or adjacent to SFS," the authors report. The standardized prevalence ratio of PBC-OLT cases near SFS was statistically significantly higher than in zip codes that did not have, nor border with, a toxi
'"/>

Contact: David Greenberg
dgreenbe@wiley.com
201-748-6484
John Wiley & Sons, Inc.
1-Mar-2006


Page: 1 2

Related medicine news :

1. Causes of primary biliary cirrhosis
2. Double the death rate from cirrhosis for blue collar men
3. Racial disparities in treatment of patients with cirrhosis and complications of portal hypertension
4. Relative risks of cirrhosis from non-alcoholic steatohepatitis
5. Increase in death rates from liver cirrhosis in Britain largest in western Europe
6. New specially coated non-stick tips stents help keep blood vessels open for cirrhosis patients
7. OPICAN study in seven Canadian cities reveals prescription opioid abuse more prevalent than heroin
8. Under-diagnosed rage disorder more prevalent than previously thought
9. Mild cognitive impairment prevalent in elderly population
10. Experts question prevalent stereotypes about autism
11. Womens silent health problem: Study finds fecal incontinence is prevalent in US women

Post Your Comments:
(Date:4/17/2014)... signs of chronic inflammation in non-cancerous prostate tissue may ... cancer than those with no inflammation, according to results ... Johns Hopkins Kimmel Cancer Center. , The link between ... with so-called high-grade prostate cancer those with a ... presence of the most aggressive and rapidly growing prostate ...
(Date:4/17/2014)... a study published today in PLOS Pathogens , ... malaria is common can mount an immune response to ... avoid repeated bouts of high fever and illness and ... bloodstream. The findings may help researchers develop future interventions ... malaria parasite. , Each year, approximately 200 million cases ...
(Date:4/17/2014)... In a review published in the April issue of ... The Feinstein Institute for Medical Research, says it,s time ... approach to treating sepsis, which kills millions ... Sepsis occurs when molecules released into the bloodstream to ... body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
(Date:4/17/2014)... By discovering a new mechanism that allows blood to ... UC Irvine and the Salk Institute have opened the ... stroke-induced brain damage. , A complex and devastating neurological ... primary reason for disability in the U.S. The blood-brain ... blood-borne material into the brain, causing the permanent deficits ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... 2014 HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... revenues for the fourth quarter of 2013 will be ... approximately $208 million. "Our full-year revenue growth ...
(Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
Cached News: